A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms CARMEN CD 307
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 14 Mar 2019 Status changed from not yet recruiting to recruiting.
- 28 Jan 2019 Planned initiation date changed from 30 Nov 2018 to 6 Feb 2019.
- 02 Oct 2018 Planned End Date changed from 31 Dec 2022 to 26 Aug 2022.